Phase 1, TAK-648, Single-Rising Dose Study

Phase 1 Completed 39 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels in healthy participants.

Timeline

Start: 2014-08
Primary completion: 2015-04
Completion: 2015-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAK-648	Unknown	0.05 mg	Oral
Subject	TAK-648	Unknown	0.15 mg	Oral
Subject	TAK-648	Unknown	0.35 mg	Oral
Subject	TAK-648	Unknown	0.7 mg	Oral
Subject	TAK-648	Unknown	0.85 mg	Oral

Indications

No indication recorded.